查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1512669

全球益生菌 IBS 补充剂市场 - 2024-2031

Global Probiotic IBS Supplements Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 235 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球益生菌IBS补充剂市场达到2,912万美元，预计2031年将达到4,879万美元，2024-2031年预测期间复合年增长率为7.65%。

益生菌已显示出缓解肠躁症症状的潜力。美国胃肠病学会的一项统合分析发现，益生菌可能有助于改善肠躁症的整体症状，包括腹胀和肠胃气胀。消费者对肠道健康益处的认识不断提高，消化系统疾病的发生率不断上升，以及对益生菌对消化以外的潜在健康影响的不断探索，推动了益生菌市场的扩张。

消费者越来越认识到益生菌对消化系统健康的潜在益处，包括控制肠躁症的症状。随着越来越多的人熟悉益生菌及其在促进肠道健康中的作用，对益生菌补充剂的需求，特别是与肠躁症等疾病相关的需求增加，推动了全球市场的增长。

北美主导全球益生菌肠躁症补充剂市场。益生菌补充剂在北美各个方面的大量应用正在积极促进该地区的市场扩张。根据国际食品资讯理事会 2022 年 4 月进行的食品与健康调查，约 33% 的美国受访者努力在饮食中添加益生菌，其中 60% 的受访者希望每天都这样做。

动力学

肠躁症的盛行率不断增加

全球肠躁症（IBS）发生率的上升是益生菌补充剂市场的重要动力。据国际胃肠道疾病基金会称，全球估计有 5-10% 的人口患有 IBS。同样，2023 年 9 月，Cedars-Sinai 研究人员的一项新研究结果显示，肠躁症比之前认为的更为普遍。大约 20% 到 40% 的胃肠病专家就诊是由于肠躁症 (IBS) 症状。

随着越来越多的人被诊断出患有肠躁症，对有效管理和缓解方案的需求不断增长，益生菌因其对肠道健康的益处而成为首选之一。许多人喜欢自然和整体的方法来管理肠躁症等健康状况。益生菌由促进健康肠道微生物群的有益细菌组成，与人们对自然疗法的偏好非常一致。

益生菌的使用不断增加

益生菌以其透过维持平衡的肠道微生物群和支持免疫功能来促进消化健康的潜力而闻名。消费者对益生菌益处的认识不断提高，推动了益生菌在包括消化健康在内的各个应用领域的广泛消费。

国际食品资讯理事会2021 年进行的一项调查显示，51% 的美国人将益生菌纳入饮食中以促进肠道健康，33% 的美国人将益生菌用于增强免疫功能，38% 的美国人将益生菌用于整体健康和保健目的， 13% 的人表示食用益生菌是为了支持情绪健康。

益生菌被认为有助于恢復肠道细菌的平衡，而肠躁症患者的肠道细菌平衡可能会被破坏。一些研究表明，某些益生菌菌株可能透过调节肠道微生物群组成、减少发炎和改善肠道屏障功能来帮助缓解 IBS 症状。据 NIH 称，许多荟萃分析评估了益生菌对 IBS 患者的影响，大多数得出的结论是益生菌在缓解症状方面具有积极作用。

药物治疗的竞争

虽然益生菌补充剂提供了一种自然而全面的方法来控制肠躁症症状，但它们面临药物治疗的竞争。解痉药、泻药和抗忧郁药等治疗药物通常用于治疗 IBS。与益生菌补充剂相比，药物治疗提供了不同的症状管理方法。

药物治疗通常针对特定症状或疾病的潜在机制。它们可以更立即地缓解腹痛、腹胀和排便不规律等症状。此外，它们通常由医疗保健专业人员开处方，为寻求症状缓解的患者提供一定程度的保证和指导。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 肠躁症的盛行率不断增加
      • 益生菌的使用不断增加
    • 限制
      • 药物治疗的竞争
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • DMI 意见

第 6 章：COVID-19 分析

第 7 章：按应变

  • 乳酸菌
  • 双歧桿菌
  • 其他

第 8 章：按形式

  • 药片
  • 胶囊
  • 液体
  • 粉末
  • 其他的

第 9 章：按配销通路

  • 超市/大卖场
  • 药局/保健品店
  • 网上商店
  • 其他

第 10 章：最终用户

  • 婴儿
  • 孩子们
  • 成年人
  • 老年人

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • The Good Bug
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Zeroharm Sciences Private Limited
  • Menoveda Life Sciences Private Limited
  • Unique Biotech Limited
  • Projoy Pvt Ltd
  • Pure NSM - Nutritional Supplement Manufacturers, Inc.
  • Nature's Bounty
  • Hyperbiotics
  • Advanced Vital Enzymes Private Ltd
  • Wren Laboratories Ltd

第 14 章：附录

简介目录
Product Code: FB8516

Overview

Global Probiotic IBS Supplements Market reached US$ 29.12 million in 2023 and is expected to reach US$ 48.79 million by 2031, growing with a CAGR of 7.65% during the forecast period 2024-2031.

Probiotics have shown a potential to relieve irritable bowel syndrome symptoms. An American College of Gastroenterology meta-analysis found that probiotics may help improve overall IBS symptoms, including bloating and flatulence. The expansion of the probiotics market is propelled by heightened consumer awareness of the benefits to gut health, a growing incidence of digestive disorders, and continuous exploration of probiotics' potential health impacts extending beyond digestion.

There's a heightened awareness among consumers regarding the potential benefits of probiotics for digestive health, including managing symptoms of IBS. As more people become familiar with probiotics and their role in promoting gut health, the demand for probiotic supplements, specifically related to conditions like IBS, increases driving the market growth worldwide.

North America dominates the global probiotic IBS supplements market. The high use of probiotic supplements in various aspects of application in North America is positively improving the market expansion in this region. According to the Food and Health Survey conducted by the International Food Information Council in April 2022, around 33% of respondents in the United States make an effort to include probiotics in their diets, with 60% aiming to do so daily.

Dynamics

Increasing Prevalence of Irritable Bowel Syndrome

The rising incidence of IBS worldwide is a significant driver for the probiotic supplements market. According to the International Foundation for Gastrointestinal Disorders, the worldwide estimation of IBS is reported to be 5-10% of the population. Similarly, in September 2023, results from a new study by Cedars-Sinai investigators revealed that irritable bowel syndrome is more prevalent than previously thought. Approximately 20 to 40% of all visits to gastroenterologists are due to IBS symptoms.

As more individuals are diagnosed with IBS, there's a growing demand for effective management and relief options, with probiotics being one of the preferred choices due to their perceived benefits in gut health. Many individuals prefer natural and holistic approaches to managing health conditions like IBS. Probiotics, which consist of beneficial bacteria that promote a healthy gut microbiota, align well with this preference for natural remedies.

Rising Use of Probiotics

Probiotics are known for their potential to promote digestive health by maintaining a balanced intestinal microbiota and supporting immune function. Increasing consumer awareness regarding the benefits of probiotics is driving the wide consumption of probiotics in various application sectors including digestive health.

In a 2021 survey conducted by the International Food Information Council, findings indicated that 51% of Americans incorporate probiotics into their diets to promote gut health, 33% use them to bolster immune function, 38% integrate probiotics for overall health and wellness purposes, and 13% reported consuming probiotics to support emotional well-being.

Probiotics are believed to help restore the balance of gut bacteria, which can be disrupted in individuals with IBS. Some studies suggest that certain probiotic strains may help relieve IBS symptoms by modulating gut microbiota composition, reducing inflammation and improving intestinal barrier function. According to NIH, numerous meta-analyses have evaluated the impact of probiotics on individuals with IBS with the majority concluding that probiotics offer a positive effect in alleviating symptoms.

Competition from Pharmaceutical Treatments

While probiotic supplements offer a natural and holistic approach to managing IBS symptoms, they face competition from pharmaceutical treatments. The treatments such as antispasmodics, laxatives and antidepressants, are commonly prescribed for IBS management. Pharmaceutical treatments offer a different approach to symptom management compared to probiotic supplements.

Pharmaceutical treatments typically target specific symptoms or underlying mechanisms of the condition. They provide more immediate relief of symptoms such as abdominal pain, bloating, and irregular bowel movements. In addition, they are often prescribed by healthcare professionals, providing a level of assurance and guidance for patients seeking symptom relief.

Segment Analysis

The global probiotic IBS supplements market is segmented based on strain, form, distribution channel, end-user and region.

Potential Benefits of Bifidobacterium

The global probiotic IBS supplements market is segmented based on strain into lactobacillus, bifidobacterium and others. The bifidobacterium segment accounted for the largest share of the global market. Bifidobacterium strains, such as Bifidobacterium infantis and Bifidobacterium longum, have been extensively studied for their potential benefits in managing symptoms of IBS.

Clinical trials and research studies have consistently shown positive outcomes, including improved abdominal pain, bloating and bowel habits. According to Harvard studies, Bifidobacterium bifidum MIMBb75, probiotic strain, has demonstrated strong adherence to intestinal cells, suggesting it may effectively modify the gut microbiota and enhance the intestinal barrier.

Clinical trials published in Alimentary Pharmacology & Therapeutics have shown that daily supplementation with Bifidobacterium bifidum MIMBb75 significantly improved overall IBS symptoms, as well as individual symptoms like abdominal pain, bloating and fecal urgency. Also, recent research has indicated that even heat-inactivated Bifidobacterium bifidum MIMBb75 can relieve IBS symptoms.

Geographical Penetration

High Prevalence of Irritable Bowel Syndrome in North America

North America dominates the global probiotic IBS supplements market. North America has a relatively high prevalence of irritable bowel syndrome, with millions of individuals affected by this condition. The International Foundation for Gastrointestinal Disorders recently reported that IBS affects between 25 and 45 million people in United States. About 2 in 3 IBS sufferers are female, while 1 in 3 IBS sufferers are male.

The large patient population creates a significant market opportunity for products targeting IBS management. With a strong culture of health and wellness in North America, many consumers actively seek natural and holistic approaches to managing health conditions like IBS. Probiotic supplements are perceived as safe and effective options for promoting digestive health and alleviating symptoms of IBS, fitting well with the preferences of health-conscious consumers in the region.

Competitive Landscape

The major global players in the market include The Good Bug, Zeroharm Sciences Private Limited, Menoveda Life Sciences Private Limited, Unique Biotech Limited, Projoy Pvt Ltd, Pure NSM - Nutritional Supplement Manufacturers, Inc., Nature's Bounty, Hyperbiotics, Advanced Vital Enzymes Private Ltd and Wren Laboratories Ltd.

COVID-19 Impact Analysis

The COVID-19 had a moderate impact on the global probiotic IBS supplements market. The probiotic supplements market, like many other industries, has been impacted by disruptions in global supply chains caused by the pandemic. Restrictions on travel, closures of manufacturing facilities and logistical challenges have led to delays in production and distribution, affecting the availability of probiotic products in some regions.

The pandemic has heightened awareness about the importance of maintaining a healthy immune system. Probiotics, known for their role in gut health, have gained attention for their potential immune-supporting properties. The greater demand for products perceived to promote overall health positively impacted the probiotic supplements market. Individuals with IBS are motivated to explore natural remedies like probiotics to support their immune and digestive health.

By Strain

  • Lactobacillus
  • Bifidobacterium
  • Other

By Form

  • Tablet
  • Capsules
  • Liquid
  • Powder
  • Others

By Distribution Channel

  • Supermarkets/Hypermarkets
  • Pharmacy/Health Stores
  • Online Stores
  • Other

By End-User

  • Infant
  • Children
  • Adults
  • Seniors

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2023, Hyperbiotics introduced PRO-IBS Support. This innovative product features a dual-action synergistic blend of Lactiplantibacillus plantarum 299v and highly bioavailable Boswellia serrata extract. The formulation aims to effectively alleviate gut discomfort and dysfunction in individuals with IBS.
  • In August 2022, researchers at the University of Nottingham secured £1.8 million in funding for a three-year project to explore the potential benefits of cellulose-based food supplements for individuals suffering from Irritable Bowel Syndrome, focusing on colon fermentation.

Why Purchase the Report?

  • To visualize the global probiotic IBS supplements market segmentation based on strain, form, distribution channel, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of probiotic IBS supplements market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global probiotic IBS supplements market report would provide approximately 70 tables, 76 figures and 235 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Strain
  • 3.2. Snippet by Form
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Irritable Bowel Syndrome
      • 4.1.1.2. Rising Use of Probiotics
    • 4.1.2. Restraints
      • 4.1.2.1. Competition from Pharmaceutical Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Strain

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 7.1.2. Market Attractiveness Index, By Strain
  • 7.2. Lactobacillus
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bifidobacterium
  • 7.4. Other

8. By Form

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 8.1.2. Market Attractiveness Index, By Form
  • 8.2. Tablet
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Capsules
  • 8.4. Liquid
  • 8.5. Powder
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Supermarkets/Hypermarkets
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Pharmacy/Health Stores
  • 9.4. Online Stores
  • 9.5. Other

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Infants
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Children
  • 10.4. Adults
  • 10.5. Seniors

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. The Good Bug
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Zeroharm Sciences Private Limited
  • 13.3. Menoveda Life Sciences Private Limited
  • 13.4. Unique Biotech Limited
  • 13.5. Projoy Pvt Ltd
  • 13.6. Pure NSM - Nutritional Supplement Manufacturers, Inc.
  • 13.7. Nature's Bounty
  • 13.8. Hyperbiotics
  • 13.9. Advanced Vital Enzymes Private Ltd
  • 13.10. Wren Laboratories Ltd

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us